MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock upon...
$544,194K
Proceeds from stock
options exercised
$52,066K
Net cash provided by
financing activities
$595,756K
Canceled cashflow
$504K
Net change in cash
and cash...
$188,139K
Canceled cashflow
$407,617K
Payment of offering and
private placement costs
$504K
Stock-based compensation
$55,724K
Accrued expenses
$45,000K
Prepaid expenses and
other current assets
-$8,844K
Accounts receivable
-$986K
Depreciation on property and
equipment
$409K
Non-cash lease expense
$99K
Other assets
-$69K
Net cash used in
operating activities
-$407,310K
Effect of exchange rate
changes on cash and cash...
-$299K
Net cash used in
investing activities
-$8K
Canceled cashflow
$111,131K
Net loss
-$505,606K
Purchases of property and
equipment
$8K
Accounts payable
-$10,252K
Income tax receivable
$2,386K
Operating lease
liabilities
-$99K
Due to roivant
sciences ltd
-$98K
Back
Back
Cash Flow
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)
source: myfinsight.com